Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials

ConclusionsRemission and LDA are feasible targets with upadacitinib treatment in patients with PsA.Trial RegistrationClinicalTrial.gov identifiers NCT03104400 (SELECT-PsA 1) and NCT03104374 (SELECT-PsA 2).
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research